Infertility? From the “Three-Parent” IVF Trialed for Infertility to current market trend discussion.
Are you ready?
- "Three-Parent"IVF Trialed for Infertility
- Incidence and treatment progress of Infertility worldwide and in China
- The key causes of Infertility
- Comparison of global and China treatment guidelines for Infertility
- Global and China pipeline of infertility research projects
- Leading players globally and in China
Event details
|
DATE Friday October 18, 2019 VENUE Webex TIME 3:00 PM - 4:00 PM RSVP This is a FREE event VIP tckets priority for Lingmed current clients Please RSVP by October 17, 2019 |
PRESENTERS Lingling Cao, CEO & Founder Hank Wang, Medical advisor REGISTER +86 21 5386 3003 |
Agenda
| 15:00 - 15:10 | Linkedbio services & projects introductions | by LingLing Cao |
| 15:10 - 15:45 | Infertility? From the “Three-Parent” IVF Trialed for Infertility to current market trend discussion. | by Hank Wang |
| 15:45 - 15:55 | Panel discussions | |
| 15:55 - 16:00 | Q&A |
Presenters
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |
 |
Hank Wang Medical advisor Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market |